Ftse Mib
33.494,83
0,60%
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
NASDAQ
19.003,65
0,16%
Bitcoin
98.667,27
-0,37%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Amneal Pharmaceuticals Holding Co (AMRX) Amneal Pharmaceuticals Holding Co (AMRX) Notizie

Amneal Pharmaceuticals Holding Co

AMRX
5,87
0,00 (0,00%)
22 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
05/9/202422:05BWAmneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the..
20/8/202417:26BWAmneal Receives U.S. FDA Approval for Propofol Injectable..
20/8/202414:00BWAmneal Receives U.S. FDA Approval for Propofol Injectable..
14/8/202421:12EDGAR2Form 144 - Report of proposed sale of securities
14/8/202417:04EDGAR2Form 144 - Report of proposed sale of securities
14/8/202411:56IHMARKETNEWSUBS Beats Earnings Forecasts, Intel Divests Arm Holdings,..
09/8/202412:05BWAmneal Reports Second Quarter 2024 Financial Results
07/8/202422:45BWAmneal Receives U.S. FDA Approval for IPX203 for Treatment..
29/7/202422:05BWAmneal Receives U.S. FDA Approval for Potassium Phosphates..
11/7/202422:05BWAmneal to Report Second Quarter 2024 Results on August 9,..
09/7/202422:05BWAmneal Launches FOCINVEZ™, the First Ready-to-Use Version of..
01/7/202414:00BWAmneal Expands Biosimilars Portfolio to Eight Products with..
28/6/202414:00BWAmneal Releases 2023 Environmental, Social and Governance..
05/6/202414:00BWAmneal Expands Broad Injectables Portfolio to Over 40..
22/5/202422:05BWAmneal Begins Supplying Over-the-Counter Naloxone..
16/5/202421:13EDGAR2Form 144 - Report of proposed sale of securities
14/5/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202422:18EDGAR2Form 8-K - Current report
06/5/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202423:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202423:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202423:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/5/202412:14EDGAR2Form 8-K - Current report
03/5/202412:00BWAmneal Reports First Quarter 2024 Financial Results
24/4/202414:00BWAmneal Announces U.S. FDA Approval of Over-the-Counter..
16/4/202414:00BWAmneal Launches PEMRYDI RTU®, the First Ready-to-Use Version..
10/4/202414:00BWAmneal to Report First Quarter 2024 Results on May 3, 2024
28/3/202421:05BWAmneal to Ring the Nasdaq Closing Bell on April 2, 2024
25/3/202421:05BWAmneal Receives U.S. FDA Approval for Ciprofloxacin and..
22/3/202413:01EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/3/202413:01EDGAR2Form DEF 14A - Other definitive proxy statements
06/3/202423:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202412:13EDGAR2Form 8-K - Current report
01/3/202412:00BWAmneal Reports Fourth Quarter and Full Year 2023 Financial..
29/2/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202414:00BWAmneal Enters into Exclusive European Licensing Agreement..
13/2/202414:00BWAmneal to Participate at Upcoming Investor Conference
08/2/202422:05GLOBEAmneal Announces Complete Response Resubmission for IPX203..
31/1/202422:05BWAmneal to Report Fourth Quarter and Full Year 2023 Results..
10/1/202414:00BWAmneal Launches Complex Generic Fluorometholone Ophthalmic..
04/1/202422:05BWAmneal Launched Record Number of 39 New Retail and..
26/12/202322:10EDGAR2Form 25 - Notification of the removal from listing and..
26/12/202322:05EDGAR2Form 8-A12B - Registration of securities [Section 12(b)]
Apertura: Min: Max:
Chiusura: 5,87

La tua Cronologia

NYSE
AMRX
Amneal Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network